Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 17/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751019 | 1.00 | CHEK2 (0.48) | CHEK2PKN1PKN2CHEK1 | |
| SCHEMBL446291 | 0.86 | MMP2 (0.42) | CHEK2PKN1PKN2CHEK1 | |
| SCHEMBL9172322 | 0.84 | MMP2 (0.41) | CHEK2PKN1PKN2CHEK1 | |
| SCHEMBL29510973 | 0.84 | TDP1 (0.51) | CHEK2 | |
| SCHEMBL264413 | 0.84 | TDP1 (0.51) | CHEK2 | |
| SCHEMBL263919 | 0.82 | SLC2A1 (0.44) | — | |
| SCHEMBL4397003 | 0.79 | TPSAB1 (0.35) | CHEK2PKN1PKN2 | |
| SCHEMBL27676330 | 0.79 | HDAC6 (0.58) | — | |
| SCHEMBL9871375 | 0.78 | KDM4E (0.52) | — | |
| SCHEMBL13446572 | 0.78 | CCNC (0.49) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101686979-A | The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces | JANSSEN PHARMACEUTICA NV | 2010-03-31 | — | — | CN | claimed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| CN-103339108-A | Protease activated receptor 2 (par2) antagonists | PROXIMAGEN LTD | 2013-10-02 | — | — | CN | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010141824-A2 | USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
| CN-1989119-A | New benzoyl urea derivatives | RICHTER GEDEON VEGYESZET (HU) | 2007-06-27 | — | — | CN | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| CN-1898227-A | As prostaglandin E2Ornithine derivatives as agonists or antagonists | ASTELLAS PHARMA INC (JP) | 2007-01-17 | — | — | CN | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | CHEK2 4825/4885PKN1 3861/4885PKN2 3911/4885 |
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | CHEK2 1757/4885PKN1 2658/4885PKN2 1495/4885 |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | HTRA1, ALDH1A2, HTRA2 | CHEK2 4339/4885PKN1 817/4885PKN2 1381/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | CHEK2 1589/4885PKN1 1867/4885PKN2 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.